Experienced in Chronic B-Cell Leukemia (CBCL)

Andrew R. Belch

Edmonton, AB, CA 
Experienced in Chronic B-Cell Leukemia (CBCL)
Edmonton, AB, CA 
OverviewLocationsClinical Research

Overview

Andrew Belch practices in Edmonton, Canada. Mr. Belch is rated as an Experienced expert by MediFind in the treatment of Chronic B-Cell Leukemia (CBCL). His top areas of expertise are Multiple Myeloma, Mantle Cell Lymphoma (MCL), Non-Hodgkin Lymphoma, Agranulocytosis, and Bone Marrow Transplant.

His clinical research consists of co-authoring 61 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 5 articles in the study of Chronic B-Cell Leukemia (CBCL).

Gender
Male

Locations

Edmonton, AB, Canada
Other Locations
Edmonton, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Contiguous, Sequential Phase I/II Imaging Study of 18F-fluoro-3'-L-fluorothymidine (18F-FLT) in Patients With Known or Suspected Carcinoma of the Lung, Breast, Renal Cell, Pancreas, or Brain, and With Gastrointestinal Malignancies, Neuroendocrine Tumours or Lymphoma
A Contiguous, Sequential Phase I/II Imaging Study of 18F-fluoro-3'-L-fluorothymidine (18F-FLT) in Patients With Known or Suspected Carcinoma of the Lung, Breast, Renal Cell, Pancreas, or Brain, and With Gastrointestinal Malignancies, Neuroendocrine Tumours or Lymphoma
Enrollment Status: Terminated
Publish Date: August 22, 2019
Intervention Type: Biological
Study Phase: Phase 1/Phase 2

60 Total Publications

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.
Journal: The Lancet. Haematology
Published: December 09, 2021

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Belch's expertise for a condition
ConditionClose
      View All 12 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile